Nuevos anticoagulantes orales / New oral anticoagulant drugs
Rev. méd. Chile
; 139(10): 1347-1355, oct. 2011. ilus, tab
Article
in Spanish
| LILACS
| ID: lil-612205
Responsible library:
BR1.1
ABSTRACT
Thromboembolic disease (TED) is the leading cause of morbidity and mortality worldwide. The hallmark of oral long-term anticoagulant therapy has been the use of vitamin K antagonists, whose anticoagulant effect is exerted inhibiting vitamin K epoxide reductase. Warfarin and acenocoumarol are the most commonly used. In the last five years several new drugs for long term anticoagulation have been developed, which can inhibit single clotting factors with the purpose of improving drug therapeutic range and, ideally, minimizing bleeding risks. This review addresses the state of the art on the clinical use of inhibitors of activated factor X and thrombin.
Full text:
Available
Collection:
International databases
Database:
LILACS
Main subject:
Vitamin K
/
Thrombin
/
Factor Xa
/
Anticoagulants
Limits:
Humans
Language:
Spanish
Journal:
Rev. méd. Chile
Journal subject:
Medicine
Year:
2011
Document type:
Article
Affiliation country:
Chile
Institution/Affiliation country:
Pontificia Universidad Católica de Chile/CL